All In Biotech

Drug Trial Radar · NCT07536269

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Neurocrine Switzerland GmbHNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 months, up to 47 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

  • CrinecerfontDrug

    Oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: Day 1 up to 28 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    San Francisco, California · Recruiting

  • Neurocrine Clinical Site

    Aurora, Colorado · Recruiting

  • Neurocrine Clinical Site

    Hartford, Connecticut · Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Chicago, Illinois · Recruiting

  • Neurocrine Clinical Site

    Indianapolis, Indiana · Recruiting

  • Neurocrine Clinical Site

    Ann Arbor, Michigan · Recruiting

  • Neurocrine Clinical Site

    Minneapolis, Minnesota · Recruiting

  • Neurocrine Clinical Site

    Philadelphia, Pennsylvania · Recruiting

  • Neurocrine Clinical Site

    Dallas, Texas · Recruiting

  • Neurocrine Clinical Site

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.